

RESEARCH

Open Access



Mutation in *WDR4* impairs tRNA m⁷G₄₆ methylation and causes a distinct form of microcephalic primordial dwarfism

Ranad Shaheen^{1†}, Ghada M H Abdel-Salam^{2†}, Michael P. Guy^{3,6†}, Rana Alomar¹, Mohamed S. Abdel-Hamid⁴, Hanan H. Afifi², Samira I. Ismail², Bayoumi A. Emam², Eric M. Phizicky^{3*} and Fowzan S. Alkuraya^{1,5}

Abstract

Background: Primordial dwarfism is a state of extreme prenatal and postnatal growth deficiency, and is characterized by marked clinical and genetic heterogeneity.

Results: Two presumably unrelated consanguineous families presented with an apparently novel form of primordial dwarfism in which severe growth deficiency is accompanied by distinct facial dysmorphism, brain malformation (microcephaly, agenesis of corpus callosum, and simplified gyration), and severe encephalopathy with seizures. Combined autozygome/exome analysis revealed a novel missense mutation in *WDR4* as the likely causal variant. *WDR4* is the human ortholog of the yeast Trm82, an essential component of the Trm8/Trm82 holoenzyme that effects a highly conserved and specific (m⁷G₄₆) methylation of tRNA. The human mutation and the corresponding yeast mutation result in a significant reduction of m⁷G₄₆ methylation of specific tRNA species, which provides a potential mechanism for primordial dwarfism associated with this lesion, since reduced m⁷G₄₆ modification causes a growth deficiency phenotype in yeast.

Conclusion: Our study expands the number of biological pathways underlying primordial dwarfism and adds to a growing list of human diseases linked to abnormal tRNA modification.

Background

Primordial dwarfism (PD) is a term used to describe a wide range of phenotypes that have in common severe prenatal growth deficiency (>3 SD below the mean) that persists postnatally [1]. Although extremely rare, the monogenic nature of PD lends itself readily to gene mapping approaches thus representing a unique resource for understanding the biological networks that control growth through the discovery of genes that are mutated in this condition [2].

Impaired DNA damage repair is among the earliest identified mechanisms in PD as revealed by the discovery that *ATR* is mutated in patients with Seckel syndrome, a clinical subtype of PD characterized by microcephaly and distinct facial features [3]. The same mechanism is

invoked in PD caused by mutations in *ATRIP*, *BRCA2*, *DNA2*, and *XRCC4* [4, 5]. Impaired mitosis due to centrosomal abnormalities has now emerged as a major mechanism underlying many forms of PD [2, 6–9]. Less common forms of PD were found to be caused by mutations in genes involved in replication licensing, splicing and serine synthesis [10–13]. Despite the remarkable acceleration of PD disease gene discovery in recent years, one-third of the cases remain undiagnosed molecularly, which suggests that additional disease genes likely exist and these might further expand the known molecular network that controls growth [4].

tRNA is a well-studied class of non-coding RNA that plays an essential role in protein synthesis by transferring amino acids to the growing peptide chain as the corresponding mRNA is being decoded by the ribosomal translational machinery. A remarkable multitude of modification reactions (>100) are known, which are often highly conserved in different organisms, including in prokaryotes and archaea, clearly suggesting their

* Correspondence: Eric_Phizicky@URMC.Rochester.edu

†Equal contributors

³Department of Biochemistry and Biophysics, Center for RNA Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Full list of author information is available at the end of the article

importance [14]. Our knowledge of the biology of tRNA modification comes primarily from work on the yeast *Saccharomyces cerevisiae* and other model organisms [15–17]. In general, modifications in the tRNA anticodon loop are critical for translational efficiency, frame maintenance, and fidelity, and lack of these modifications often leads to lethality, slow growth, and/or other phenotypic effects [16, 18]. Modifications to the body of the tRNA are generally involved in tRNA folding and stability [19–22], and lack of any of several different body modifications in yeast causes temperature sensitivity due to rapid tRNA decay (RTD) of specific tRNAs [23–25].

The recent identification of several links between tRNA modification and human disease have spurred increased interest in this field and its potential to explain the pathogenesis of clinically relevant disorders [26]. In this study, we describe an apparently novel clinical condition characterized by primordial dwarfism and a unique set of additional features. We show that the two families affected by this disorder map to *WDR4*, the human ortholog of Trm82, which is required for formation of the highly conserved m⁷G₄₆ (7-methylguanosine) modification of tRNA. The m⁷G₄₆ modification occurs widely in prokaryotes and eukaryotes [14], and in *S. cerevisiae* requires a holoenzyme comprised of the Trm8 methyltransferase subunit and its WD40 repeat-containing binding partner Trm82 [27], which appears to be involved in maintaining Trm8 levels [28], and in helping Trm8 maintain an active conformation [29]. Yeast *trm82Δ* mutants, like *trm8Δ* mutants, are mildly temperature sensitive due to lack of m⁷G in their tRNA [28], and have synthetic genetic interactions with *trm4Δ* mutants (lacking m⁵C), and a number of other modification mutants, resulting in a severe temperature sensitive growth defect [23]. Human *WDR4* and *METTL1* are the likely orthologs of *S. cerevisiae* *TRM82* and *TRM8* based on homology, and on their complementation of yeast mutants lacking m⁷G₄₆ [27]. Here we show that the *WDR4* mutation affects m⁷G₄₆ methylation suggesting a potential mechanism for this novel form of PD.

Results

Identification of a novel PD syndrome

Patient 1 (14DG1157)

This female infant was born to a 20-year-old mother and 26-year-old father by normal vaginal delivery at 37-weeks' gestation. The parents are healthy first cousins (Fig. 1a). The family history is non-contributory. The couple had a subsequent boy who died a few days after birth because of growth retardation and multiple congenital heart anomalies. During the gestation of patient 1, the pregnancy was complicated by threatened abortion in the

first trimester. Intrauterine growth retardation and weak fetal movements were also documented. The birth weight was 1,600 g. The birth length and head circumference were not recorded but mentioned to be small. She was referred to the Clinical Genetics Department at the age of 4 months because of poor gain of weight and for genetic counseling. On clinical examination she was noted to have a head circumference of 31.5 cm (–5 SD) weight of 2,800 g (–6 SD), and length of 48 cm (–5 SD). The patient had a high forehead, prominent eyes, depressed nasal bridge, short philtrum, tented upper lip and bulged alveolar ridge, and prominent ear lobule (Fig. 1b).

Her neurological evaluation revealed hypertonia, brisk deep-tendon reflexes, with flexor plantar responses. At that age, radiological examination showed unossified pubic bones, proportionately short femora, and broad metaphyses of the femora and tibiae. The tibiae and fibulae were short and equal in length.

At the age of 10 months, she developed seizures with only partial response to valproate and lamotrigine. EEG records revealed low voltage slow waves (3–6 cycles/s) mixed with sleep spindle.

At the age of 20 months, her weight, length, and head circumference were 3,500 g (–6.5 SD), 55 cm (–9.5 SD), and 32 cm (–10.7 SD), respectively. The girl was spastic with contracture deformity in the elbows and hands. Her neurological evaluation revealed hypertonia, brisk deep-tendon reflexes, with flexor plantar responses. She had not acquired any developmental milestones and never recognized her mother. Abdominal ultrasonography and echocardiography showed normal results. Ophthalmological examination showed bilateral optic atrophy.


Chromosomal examination from peripheral blood lymphocytes and high resolution banding technique revealed normal female karyotype 46,XX.

Cranial MRI showed partial agenesis of corpus callosum, and abnormal gyral pattern most pronounced posteriorly.

Diagnosis of microcephalic primordial dwarfism was made at this time based on significant pre- and post-natal growth retardation. Because of the partial overlap with microcephalic osteodysplastic primordial dwarfism I, analysis of *RNU4ATAC* was undertaken but revealed negative results.

Patient 2 (14DG1160)

Patient 2 was the fifth child born to a 36-year-old mother and 39-year-old father. The parents are maternal and paternal first cousins (double consanguineous) (Fig. 1a). The second pregnancy resulted in a similarly affected boy who died at the age of 9 months because of pneumonia accompanied by uncontrolled seizures. A postmortem examination was not performed. There was no other family history of note. Patient 2 was delivered vaginally weighing 1,500 g (–3.7 SD) at 38 weeks'



gestation. Her birth length and head circumference were not recorded. At age 4 months she experienced focal seizures that later evolved into generalized tonic-clonic seizures controlled by combination sodium valproate, levetiracetam, and lamotrigine therapy. EEG records revealed high voltage delta waves (2–4 cycles/s). Abdominal ultrasonography and echocardiography showed normal results.

At the age of 7 months, she was referred to our Clinical Genetics Department because of the microcephaly and poor weight gain for genetic counseling. On examination, her weight, length and head circumference were 4,200 g (–4.7 SD), 53 cm (–5.7 SD), and 33.2 cm (–7 SD), respectively. Her facial features were quite similar to patient 1 showing rounded face with high forehead, prominent eyes, depressed nasal bridge, short philtrum, bow shaped mouth, and prominent alveolar ridge (Fig. 1c). Her neurological evaluation revealed hypertonia, brisk deep-tendon reflexes, with flexor plantar responses. Ophthalmological examination showed bilateral optic atrophy.

She presented at the age of 9 months with high fever and chest infection that diagnosed as pneumonia. This was accompanied by status epilepticus and she went into coma for 30 days.

Follow-up at the age of 17 months, her weight, length, and head circumference were 6,500 g (–3.8 SD), 60 cm (–6.7 SD), and 34.5 cm (–8.9 SD), respectively. The girl made almost no developmental progress and could not recognize the surroundings. Oro-dental examination showed thick alveolar ridge more in the upper than lower and high arched palate.

Routine biochemical and metabolic screening parameters were within normal ranges.

Chromosomal examination from peripheral blood lymphocytes and high resolution banding technique revealed normal female karyotype 46,XX. Radiographic examination of the long bones showed proportionately short long bones with broad metaphyses.

Cranial MRI showed partial agenesis of corpus callosum, and abnormal gyral pattern most pronounced posteriorly (Fig. 1d–g).

No developmental progress was observed on the last examination of both patients. They were not able to raise their heads or roll, and never laughed. They were unable to follow visually, recognize their mothers, or make eye-to-eye contact. There were no vocalizations beyond an infrequent moaning when in discomfort. Patient 2 sometimes required a tube feeding at the age of 9 months.

since residue K223 of yeast Trm82 (corresponding to R170 in human WDR4) forms a salt bridge with residue E204 of Trm8 that is speculated to be important for maintaining Trm8 in an active conformation (Fig. 3a) [29]. We therefore used *S. cerevisiae* as a model to analyze the effects of the *WDR4-R170L* mutation. We generated a low copy (*CEN*) plasmid expressing the *S. cerevisiae trm82-K223L* from its native promoter (*CEN LEU2* P_{TRM82} -*trm82-K223L*) to test its ability to complement an *S. cerevisiae trm82Δ* mutant in a *trm4Δ* background, to amplify the growth defects of the *trm82Δ* mutation [23, 28]. We also generated plasmids bearing a *trm82-K223R* variant to determine if, as expected, arginine and lysine residues are interchangeable at this location, and a *trm82-K223E* variant to test the effects of completely abrogating the salt bridge.

We found that expression of *trm82-K223L* suppressed the growth defect of the *trm82Δ trm4Δ* strain at temperatures up to 37 °C on rich (YP + dextrose) or minimal medium (S -Leu + dextrose), but not at 39 °C (Fig. 3b), indicating that the Trm82-K223L variant is defective for function at high temperature, but is not a complete loss-of-function mutation. By contrast, expression of *trm82-K223E* did not suppress the growth defect of a *trm82Δ trm4Δ* strain at any temperature, consistent with a null phenotype, whereas expression of *trm82-K223R* suppressed the defect at all temperatures (Fig. 3b), demonstrating that arginine and lysine are interchangeable at this residue.

To determine the extent to which m⁷G levels were affected in the *trm82-K223L* mutant (*trm82Δ (CEN LEU2 P_{TRM82}-trm82-K223L)*), we analyzed modification levels




Fig. 3 The *WDR4-R170L* mutation results in decreased levels of m⁷G on tRNA. **a** Predicted location of R170 residue of WDR4, based on the yeast Trm8-Trm82 crystal structure. Representation of *S. cerevisiae* Trm8-Trm82 holoenzyme (PDB 2VDU), Trm82 is light gray with residue K223 in red, and Trm8 is in dark gray with residue E204 in blue. Corresponding WDR4 and METTL1 residues are in brackets. **b** A *trm82Δ trm4Δ (CEN LEU2 P_{TRM82}-trm82-K223L)* strain has a growth defect at high temperature. Wild type and *trm82Δ trm4Δ* strains with (*LEU2*) plasmids expressing *TRM82* variants as indicated were grown overnight in S -Leu medium containing dextrose, diluted to OD₆₀₀ of approximately 0.5 in H₂O, and serially diluted 10-fold in H₂O, and then 2 μL was spotted onto indicated media, followed by incubation for 3 days as indicated. **c** Nucleoside analysis of tRNA^{Phe} purified from human LCLs derived from a PD patient homozygous for the *WDR4-R170L* allele. tRNA^{Phe} isolated from LCLs derived from the *WDR4-R170L* proband with PD, and from control LCLs, was digested to nucleosides and analyzed by HPLC as described in Materials and Methods

of two of the 11 yeast tRNA species known to have m⁷G after growth at 30 °C or 37 °C, by purification of the corresponding tRNA species from bulk RNA, followed by nuclease digestion and analysis of nucleosides by HPLC. Strikingly, we found that tRNA^{Phe} from the *trm82-K223L* mutant had no detectable m⁷G after growth at 37 °C, but only mildly reduced m⁷G levels after growth at 30 °C, compared to levels in the wild type or the *trm82-K223R* controls (0.21 moles/mole vs. 0.34 or 0.32, respectively; Table 1). Other modifications of tRNA^{Phe} were unaffected in the *trm82* mutants. By contrast, we observed a milder reduction in m⁷G levels of tRNA^{Val(AAC)} from the *trm82-K223L* strain after growth at 37 °C, compared to that from the wild type or *trm82-K223R* controls (0.25 moles/mole vs. 0.50 and 0.55, respectively; Table 1), and no obvious reduction in m⁷G levels of tRNA^{Val(AAC)} when strains were grown at 30 °C (0.45 moles/mole vs. 0.53 and 0.46, respectively; Table 2). The temperature-sensitive reduction in m⁷G levels found on both tRNA^{Phe} and tRNA^{Val(AAC)} from the *trm82-K223L* mutant is consistent with its temperature sensitive complementation of a *trm82Δ trm4Δ* strain (Fig. 3b).

We note that growth of the *trm82Δ* and *trm82-K223L* strains at 37 °C resulted in substantially increased levels of m⁵C on tRNA^{Val(AAC)} (Table 2), similar to the increase in m⁵C levels observed previously when wild type cells were grown under stress conditions [30–32]. Unexpectedly, tRNA^{Val(AAC)} in the *trm82Δ* mutant also had acquired an m²G modification (0.54 and 0.45 moles/mole at 30 °C and 37 °C, respectively, compared to barely detectable levels in the wild type strain). Since tRNA^{Val(AAC)} in the *trm82-K223L* strain acquired 0.17 moles/mole m²G at 37 °C relative to wild type

(from 0.10 to 0.27 moles/mole) while m⁷G levels were reduced by 0.25 moles/mole (from 0.50 to 0.25), we speculate that m²G levels inversely correlate with m⁷G levels on this tRNA. Other tRNA^{Val(AAC)} modifications (pseudouridine, inosine, and m¹G) were unaffected by the *trm82* mutations (Table 2).

Cells derived from a patient homozygous for the *WDR4-R170L* allele have decreased levels of m⁷G on tRNA

To further define the defect of the *WDR4-R170L* allele and its relationship to PD, we analyzed the m⁷G levels in tRNA^{Val(AAC)} and tRNA^{Phe} purified from lymphoblastoid cell lines (LCLs) derived from the PD patient 1 (14DG1160), as well as from control LCLs derived from the healthy mother (heterozygous) and a healthy brother (homozygous wild type *WDR4*). We found a substantial decrease in m⁷G on tRNA^{Phe} from the PD LCL (0.08 moles/mole in the *WDR4-R170L* homozygote vs. 0.49 and 0.46 for the homozygous wild type *WDR4* LCL and the heterozygous LCL, respectively; Fig. 3c; Table 3), similar to m⁷G levels in tRNA^{Phe} from the corresponding yeast *trm82-K223L* mutant (Table 1). By contrast, levels of the control tRNA^{Phe} modifications Cm, Gm, m²G, pseudouridine, and m⁵C modifications were similar in all of the LCLs. We also observed a minor reduction of m⁷G on tRNA^{Val(AAC)} (0.35 moles/mole in the *WDR4-R170L* homozygote vs. 0.52 and 0.46 for the wild type *WDR4* homozygote and heterozygotes, respectively; Table 3), with similar amounts of each of four control modifications observed in the three different LCLs. Thus, our results strongly suggest that the *WDR4-R170L* mutation causes defects in m⁷G₄₆ modification in the PD patients.

Table 1 HPLC analysis of tRNA^{Phe} nucleoside content from an *S. cerevisiae trm82Δ* strain expressing *TRM82* variants

Mod.	Mol. exp.	wt (<i>CEN vec</i>)	<i>trm82Δ</i> (<i>CEN TRM82</i>)	<i>trm82Δ</i> (<i>CEN vec</i>)	<i>trm82Δ</i> (<i>CEN trm82-K223L</i>)	<i>trm82Δ</i> (<i>CEN trm82-K223R</i>)
30 °C						
m ⁷ G	1	0.41 ± 0.04	0.34 ± 0.03	<0.03	0.21 ± 0.01	0.32 ± 0.04
Ψ	2	2.09 ± 0.06	1.94 ± 0.03	1.85 ± 0.04	1.99 ± 0.07	2.06 ± 0.05
Cm	1	0.89 ± 0.09	0.92 ± 0.05	0.93 ± 0.08	0.95 ± 0.03	0.93 ± 0.06
Gm	1	0.72 ± 0.01	0.76 ± 0.07	0.76 ± 0.03	0.73 ± 0.08	0.75 ± 0.02
m ⁵ C	2	1.53 ± 0.06	1.64 ± 0.07	1.69 ± 0.03	1.66 ± 0.06	1.59 ± 0.03
m ² G	1	0.78 ± 0.02	0.83 ± 0.04	0.87 ± 0.02	0.83 ± 0.04	0.82 ± 0.03
37 °C						
m ⁷ G	1	0.37 ± 0.03	0.21 ± 0.03	<0.03	<0.03	0.18 ± 0.02
Ψ	2	2.00 ± 0.08	1.91 ± 0.06	1.87 ± 0.01	1.82 ± 0.10	1.92 ± 0.01
Cm	1	0.98 ± 0.08	1.00 ± 0.14	0.91 ± 0.02	0.93 ± 0.05	0.90 ± 0.04
Gm	1	0.77 ± 0.03	0.84 ± 0.02	0.91 ± 0.05	0.96 ± 0.02	0.84 ± 0.02
m ⁵ C	2	1.63 ± 0.03	1.69 ± 0.02	1.79 ± 0.05	1.76 ± 0.04	1.71 ± 0.02
m ² G	1	0.82 ± 0.05	0.88 ± 0.02	0.90 ± 0.07	0.94 ± 0.06	0.86 ± 0.02

Mean and standard deviation based on three individual growths and RNA preparations

Table 2 HPLC analysis of tRNA^{Val(AAC)} nucleoside content from an *S. cerevisiae* *trm82Δ* strain expressing *TRM82* variants

Mod.	Mol. exp.	wt (<i>CEN</i> vec)	<i>trm82Δ</i> (<i>CEN TRM82</i>)	<i>trm82Δ</i> (<i>CEN</i> vec)	<i>trm82Δ</i> (<i>CEN trm82-K223L</i>)	<i>trm82Δ</i> (<i>CEN trm82-K223R</i>)
30 °C						
m ⁷ G	1	0.50 ± 0.07	0.53 ± 0.03	<0.03	0.45 ± 0.05	0.46 ± 0.07
Ψ	4	3.66 ± 0.10	3.87 ± 0.18	3.94 ± 0.18	3.89 ± 0.15	3.64 ± 0.08
I	1	0.76 ± 0.02	0.85 ± 0.07	0.91 ± 0.06	0.90 ± 0.05	0.77 ± 0.01
m ⁵ C	1	0.87 ± 0.03	0.94 ± 0.03	1.14 ± 0.05	0.97 ± 0.05	0.91 ± 0.03
m ¹ G	1	0.81 ± 0.05	0.98 ± 0.05	0.99 ± 0.05	1.00 ± 0.08	0.83 ± 0.05
m ² G	0	0.03 ± 0.01	0.05 ± 0.01	0.54 ± 0.10	0.07 ± 0.02	0.05 ± 0.01
37 °C						
m ⁷ G	1	0.61 ± 0.04	0.50 ± 0.07	<0.03	0.25 ± 0.03	0.55 ± 0.11
Ψ	4	3.88 ± 0.10	3.93 ± 0.05	3.85 ± 0.15	3.99 ± 0.20	4.10 ± 0.08
I	1	0.80 ± 0.01	0.77 ± 0.02	0.74 ± 0.06	0.78 ± 0.07	0.85 ± 0.04
m ⁵ C	1	1.04 ± 0.04	1.19 ± 0.04	1.53 ± 0.08	1.42 ± 0.09	1.16 ± 0.07
m ¹ G	1	0.87 ± 0.01	0.79 ± 0.03	0.79 ± 0.10	0.87 ± 0.06	0.94 ± 0.01
m ² G	0	0.05 ± 0.03	0.10 ± 0.03	0.45 ± 0.03	0.27 ± 0.05	0.06 ± 0.01

Mean and standard deviation based on three individual growths and RNA preparations

Discussion

Our results demonstrate a clear temperature sensitivity in yeast caused by the *trm82-K223L* mutation, as reflected by m⁷G levels in both tRNA^{Phe} and tRNA^{Val(AAC)}, and a clear importance of the identity of residue 223, based on the complete lack of complementation of a *trm82-K223E* mutant. These results cause us to speculate that the Trm82-K223 variant might itself be temperature sensitive, or have a temperature sensitive interaction with Trm8, through the salt bridge described between K223 of Trm82 and E204 of Trm8 [29]. It also seems highly likely that the *WDR4-R170L* allele encodes a protein with similar biochemical properties to the Trm82-K223L variant, based on the high degree of conservation between these regions of Trm82 and WDR4, as

well as the similarly reduced levels of m⁷G modification in the *WDR4-R170L* LCLs.

Several human disorders have been associated with perturbation of tRNA modification, although the level of evidence in support of causal links varies. For example, several tRNA modification genes have been found to be significantly dysregulated in various cancers and some have even been used as specific biomarkers, for example, TRMT2A in breast cancer [33]. Associations between variants in genes involved in tRNA modifications and some phenotypes have been reported, for example, *ELP4* and epilepsy, and *IKBKAP* and bronchial asthma [34, 35]. A more directly causal connection was established for several Mendelian disorders. We previously reported that a point mutation in *ADAT3* causes intellectual disability

Table 3 HPLC analysis of tRNA^{Phe} and tRNA^{Val(AAC)} nucleoside content from human LCLs

Mod.	Mol. exp.	<i>WDR4/WDR4</i>	<i>WDR4/wdr4-R170L</i>	<i>wdr4-R170L/wdr4-R170L</i>
tRNA ^{Phe}				
m ⁷ G	1	0.49 ± 0.10	0.46 ± 0.14	0.08 ± 0.02
Ψ	4	3.52 ± 0.06	3.82 ± 0.15	3.53 ± 0.15
Cm	1	0.71 ± 0.10	0.73 ± 0.02	0.86 ± 0.03
Gm	1	0.71 ± 0.07	0.63 ± 0.20	0.70 ± 0.17
m ⁵ C	1	0.61 ± 0.06	0.63 ± 0.04	0.88 ± 0.04
m ² G	1	0.78 ± 0.05	0.66 ± 0.02	0.68 ± 0.05
tRNA ^{Val(AAC)}				
m ⁷ G	1	0.52 ± 0.08	0.46 ± 0.02	0.35 ± 0.06
Ψ	3	3.10 ± 0.08	3.07 ± 0.11	2.94 ± 0.16
I	1	0.40 ± 0.03	0.39 ± 0.01	0.33 ± 0.04
m ⁵ C	2	1.66 ± 0.09	1.70 ± 0.09	1.58 ± 0.20
m ² G	1	0.90 ± 0.09	0.87 ± 0.11	0.76 ± 0.01

Mean and standard deviation based on three individual growths and RNA preparations

[36]. *ADAT3* encodes the likely homolog of yeast *TAD3*, which is the non-catalytic subunit of the complex required for I_{34} modification of substrate tRNAs [37]. Thus, the association of *WDR4* with PD is the second report of a mutation in the non-catalytic subunit of a tRNA modification enzyme that results in disease. More closely related to the PD phenotype we report in this paper are previously reported mutations in *TRM10A*, the likely human homolog of yeast *TRM10* required for m^1G_9 modification [38], which cause microcephaly and short stature [39, 40]. Similarly, mutations in human *NSUN2*, which is required for m^5C modification of body residues 48, 49, and 50 in mammals, as well as C_{34} of the anticodon [41, 42], cause variable phenotypes that include microcephaly as a feature [41, 43].

The pathogenesis of Mendelian diseases caused by tRNA modification genes remains unclear but the predilection to CNS involvement [26, 44] raises interesting possibilities about the vulnerability of the brain to any perturbation in the tight regulation of tRNA modification and, presumably, the consequences of such perturbation on protein synthesis. The mutation we previously reported in *ADAT3*, for example, is now the single most common cause of autosomal recessive intellectual disability in Saudi Arabia [45]. In this regard, the neurological phenotype we observed in patients with *WDR4* mutation (severe microcephaly, agenesis of corpus callosum, and lissencephaly) appears to follow the same pattern of bias towards brain involvement.

Severe growth deficiency in the syndrome we describe is not limited to the brain but rather generalized, resulting in microcephalic primordial dwarfism. It is unclear if this phenotype is caused by reduced proliferation, increased apoptosis or a combination of the two. Our finding that LCLs derived from a PD patient homozygous for the *WDR4-R170L* allele had drastically reduced levels of m^7G in their tRNA^{Phe} and modestly reduced m^7G in their tRNA^{Val(AAC)} strongly suggests that defective modification is a major contributor to the disease pathogenesis in these patients. However, it is not clear if the PD is caused specifically by the m^7G defects in tRNA^{Phe} and/or tRNA^{Val(AAC)}, by defects in one or more of the other five human tRNA species known to have m^7G_{46} [14], or by defects in other uncharacterized tRNA species. We note that yeast mutants lacking modifications often have growth defects due to only a subset of the tRNA species lacking those modifications [46].

The reduction in m^7G levels in human tRNAs might result in degradation of one or more specific tRNA species, resulting in reduced or aberrant translation. Yeast mutants lacking m^7G , or m^7G and m^5C , in their tRNA are temperature sensitive for growth due to 5'-3' exonucleolytic degradation of tRNA^{Val(AAC)} by the RTD pathway, which degrades the tRNA because of its more

exposed 5' end [23–25]. Similarly, HeLa cells treated with siRNA to *METTL1* and *NSUN2* to reduce m^7G and m^5C modification undergo loss of tRNA^{Val(AAC)} and an accompanying loss of cell viability upon 5-fluorouracil treatment [47]. Reduced levels of specific tRNA species due to reduced m^7G levels would be expected to lead to defects in translation and/or reduced growth. However, it is not known if there are other translation effects specifically due to reduced levels of m^7G on tRNA, as has been reported for some modifications in the anticodon loop under certain growth conditions [48].

Conclusion

Our demonstration that PD patients with the *WDR4-R170L* missense mutation have defects in m^7G levels on tRNA adds to the list of nine known or predicted human modification genes for which mutations have been strongly linked to human disease or pathologies [36, 39–41, 43, 49–60]. The underlying molecular causes of these disease associations, and why specific modification defects appear to result in specific disease manifestations remains to be determined. Interestingly, there are forms of microcephalic PD caused by impaired splicing [10], presumably resulting in impaired protein synthesis, and this may also be invoked as a potential mechanism in PD patients with abnormal tRNA modification although future research will be required to investigate that possibility.

Materials and methods

Human subjects

PD was defined as growth parameters >3 SD below the mean at birth that persist postnatally. Patients were enrolled only after their parents signed a written informed consent form under an IRB-approved protocol (KFSHRC RAC#2080006). Venous blood was collected in EDTA tubes and, when possible, in sodium heparin tubes for DNA extraction and LCL establishment, respectively. The research was carried out in accordance with the principles of the Declaration of Helsinki.

Autozygosity mapping and exome sequencing

Autozygosity mapping was performed as described before [61]. Briefly, genome-wide genotyping using Axiom SNP chip array was followed by mapping of runs of homozygosity (ROH) >2 Mb in size as surrogates of autozygosity using AutoSNPa [62], which also delineates the haplotype structure thus allowing the detection of haplotype sharing across families. Exome capture was performed using TruSeq Exome Enrichment kit (Illumina) following the manufacturer's protocol. Samples were prepared as an Illumina sequencing library, and in the second step, the sequencing libraries were enriched for the desired target using the Illumina Exome Enrichment protocol. The captured libraries were sequenced

using Illumina HiSeq 2000 Sequencer. The reads were mapped against UCSC hg19 (<http://genome.ucsc.edu/>) by BWA (<http://bio-bwa.sourceforge.net/>). The SNPs and Indels were detected by SAMTOOLS (<http://samtools.sourceforge.net/>). Variants from WES were filtered such that only novel (or very low frequency 0.1 %), coding/splicing, homozygous variants that are within the autozygome of the affected fetus and are predicted to be pathogenic were considered as likely causal variants [63]. Frequency of variants was determined using publically available variant databases (1000 Genomes, Exome Variant Server, and ExAC) as well as a database of 630 in-house ethnically-matched exomes. Pathogenicity was likely if the mutation is loss of function (splicing/truncating) or, in the case of missense/in-frame indels, removes a highly conserved amino acid and is predicted to be pathogenic by the three *in silico* prediction modules PolyPhen, SIFT, and CADD.

Yeast strains and plasmids

Wild-type BY4741 (*MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0*), its *trm82Δ::kanMX* derivative, and the homozygous *trm82Δ::natMX trm4Δ::kanMX* diploid (AA0176) were described previously [23], as was the (*CEN LEU2 P_{TRM82}-TRM82*) plasmid (AVA0279). Plasmids expressing the *S. cerevisiae* *TRM82-K223L* (pMG569A), *TRM82-K223R* (pMG570A), and *TRM82-K223E* (pMG571A) variants were generated by QuickChange PCR according to manufacturer's instructions (Stratagene), and the variant gene was then ligated into the original parent vector to eliminate mutations in the vector that could be introduced by PCR. All plasmids were confirmed by sequencing before use.

Isolation and purification of tRNA from human and yeast cells

LCLs were grown at 37 °C in 5 % CO₂ in RPMI 1640 medium containing FBS (15 %), penicillin (1 U/mL), streptomycin (1 μg/mL), and amphotericin b (0.5 μg/mL) to a density of approximately 1.0 × 10⁶ cells/mL, and bulk RNA from approximately 3.6 × 10⁸ cells was extracted with TRIzol (Life Technologies) according to manufacturer's instructions. *S. cerevisiae* strains were grown at indicated temperatures to mid-log phase in synthetic (S) dropout media containing dextrose, and bulk low molecular weight RNA was extracted from 300 OD-mL pellets as previously described [38]. For purification of individual tRNAs, appropriate 5' biotinylated oligonucleotides were used to first purify tRNA^{Phe} from RNA preparations as previously described [38], followed by purification of tRNA^{Val(AAC)} from the remaining bulk RNA.

HPLC analysis of tRNA

Purified tRNA was digested with P1 nuclease and phosphatase as previously described [38], and nucleosides

were subjected to HPLC analysis at pH 7.0 as previously described [64].

Data availability

Data used in this paper come from a small and well-defined family. To protect the identity of individuals, these confidential data are not publicly available.

Consent

Written informed consent was obtained from the patient's guardian/parent/next of kin for the publication of this report and any accompanying images.

Additional files

Additional file 1: Table S1. List of survived rare variants observed in each patient after applying the various filters. (XLSX 12 kb)

Additional file 2: Table S2. The SNP calls in the haplotype around the mutation in both probands. (XLSX 16 kb)

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

RS: collected and analyzed data and wrote the manuscript. GMHA-S: collected and analyzed data and wrote the manuscript. MPG: collected and analyzed data and wrote the manuscript. RA: collected and analyzed data. MSA-H: collected and analyzed data. HHA: collected and analyzed data. SIL: collected and analyzed data. BAE: collected and analyzed data. EMP: collected and analyzed data and wrote the manuscript. FSA: collected and analyzed data and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors thank the study families for their enthusiastic participation. They also thank the Genotyping and Sequencing Core Facilities at KFSHRC for their technical help. This work was supported in part by KSCDR grant (FSA) and National Institutes of Health grant GM052347 (EMP).

Author details

¹Department of Genetics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. ²Clinical Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo, Egypt. ³Department of Biochemistry and Biophysics, Center for RNA Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA. ⁴Medical Molecular Genetics Department, Human Genetics and Genome Research Division, National Research Centre, Cairo, Egypt. ⁵Department of Anatomy and Cell Biology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. ⁶Current address: Department of Chemistry, Northern Kentucky University, Highland Heights, KY, USA.

Received: 19 June 2015 Accepted: 14 September 2015

Published online: 28 September 2015

References

1. Alkuraya FS. Primordial dwarfism: an update. *Curr Opin Endocrinol Diabetes Obes.* 2015;22:55–64.
2. Klingseisen A, Jackson AP. Mechanisms and pathways of growth failure in primordial dwarfism. *Genes Dev.* 2011;25:2011–24.
3. O'Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA. A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. *Nat Genet.* 2003;33:497–501.
4. Shaheen R, Faqeih E, Ansari S, Abdel-Salam G, Al-Hassnan ZN, Al-Shidi T, et al. Genomic analysis of primordial dwarfism reveals novel disease genes. *Genome Res.* 2014;24:291–9.

5. Ogi T, Walker S, Stiff T, Hobson E, Limsirichaikul S, Carpenter G, et al. Identification of the first ATRIP-deficient patient and novel mutations in ATR define a clinical spectrum for ATR-ATRIP Seckel syndrome. *PLoS Genet*. 2012;8:e1002945.
6. Rauch A, Thiel CT, Schindler D, Wick U, Crow YJ, Ekici AB, et al. Mutations in the pericentrin (PCNT) gene cause primordial dwarfism. *Science*. 2008;319:816–9.
7. Shaheen R, Faqeih E, Shamseldin HE, Noche RR, Sunker A, Alshammari MJ, et al. POC1A truncation mutation causes a ciliopathy in humans characterized by primordial dwarfism. *Am J Hum Genet*. 2012;91:330–6.
8. Shaheen R, Al Tala S, Almoisheer A, Alkuraya FS. Mutation in PLK4, encoding a master regulator of centriole formation, defines a novel locus for primordial dwarfism. *J Med Genet*. 2014;51:814–6.
9. Kalay E, Yigit G, Aslan Y, Brown KE, Pohl E, Bicknell LS, et al. CEP152 is a genome maintenance protein disrupted in Seckel syndrome. *Nat Genet*. 2011;43:23–6.
10. He H, Liyanarachchi S, Akagi K, Nagy R, Li J, Dietrich RC, et al. Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I. *Science*. 2011;332:238–40.
11. Bicknell LS, Bongers EM, Leitch A, Brown S, Schoots J, Harley ME, et al. Mutations in the pre-replication complex cause Meier-Gorlin syndrome. *Nat Genet*. 2011;43:356–9.
12. Guernsey DL, Matsuoka M, Jiang H, Evans S, Macgillivray C, Nightingale M, et al. Mutations in origin recognition complex gene ORC4 cause Meier-Gorlin syndrome. *Nat Genet*. 2011;43:360–4.
13. Shaheen R, Rahbeeni Z, Alhashem A, Faqeih E, Zhao Q, Xiong Y, et al. Neu-Laxova syndrome, an inborn error of serine metabolism, is caused by mutations in PHGDH. *Am J Hum Genet*. 2014;94:898–904.
14. Machnicka MA, Milanowska K, Osman Oglou O, Purta E, Kurkowska M, Olchowski A, et al. MODOMICS: a database of RNA modification pathways—2013 update. *Nucleic Acids Res*. 2013;41:D262–267.
15. Towns WL, Begley TJ. Transfer RNA methyltransferases and their corresponding modifications in budding yeast and humans: activities, predications, and potential roles in human health. *DNA Cell Biol*. 2012;31:434–54.
16. Hopper AK. Transfer RNA, post-transcriptional processing, turnover, and subcellular dynamics in the yeast *Saccharomyces cerevisiae*. *Genetics*. 2013;194:43–67.
17. Phizicky EM, Hopper AK. tRNA biology charges to the front. *Genes Dev*. 2010;24:1832–60.
18. Agris PF, Vendeix FA, Graham WD. tRNA's wobble decoding of the genome: 40 years of modification. *J Mol Biol*. 2007;366:1–13.
19. Hall KB, Sampson JR, Uhlenbeck OC, Redfield AG. Structure of an unmodified tRNA molecule. *Biochemistry*. 1989;28:5794–801.
20. Yue D, Kintanar A, Horowitz J. Nucleoside modifications stabilize Mg²⁺ binding in *Escherichia coli* tRNA(Val): an imino proton NMR investigation. *Biochemistry*. 1994;33:8905–11.
21. Helm M, Giege R, Florentz C. A Watson-Crick base-pair-disrupting methyl group (m1A9) is sufficient for cloverleaf folding of human mitochondrial tRNA_{Lys}. *Biochemistry*. 1999;38:13338–46.
22. Whipple JM, Lane EA, Chernyakov I, D'Silva S, Phizicky EM. The yeast rapid tRNA decay pathway primarily monitors the structural integrity of the acceptor and T-stems of mature tRNA. *Genes Dev*. 2011;25:1173–84.
23. Alexandrov A, Chernyakov I, Gu W, Hiley SL, Hughes TR, Grayhack EJ, et al. Rapid tRNA decay can result from lack of nonessential modifications. *Mol Cell*. 2006;21:87–96.
24. Chernyakov I, Whipple JM, Kotelawala L, Grayhack EJ, Phizicky EM. Degradation of several hypomodified mature tRNA species in *Saccharomyces cerevisiae* is mediated by Met22 and the 5'-3' exonucleases Rat1 and Xrn1. *Genes Dev*. 2008;22:1369–80.
25. Dewe JM, Whipple JM, Chernyakov I, Jaramillo LN, Phizicky EM. The yeast rapid tRNA decay pathway competes with elongation factor 1A for substrate tRNAs and acts on tRNAs lacking one or more of several modifications. *RNA*. 2012;18:1886–96.
26. Torres AG, Battle E, de Poupiana LR. Role of tRNA modifications in human diseases. *Trends Mol Med*. 2014;20:306–14.
27. Alexandrov A, Martzen MR, Phizicky EM. Two proteins that form a complex are required for 7-methylguanosine modification of yeast tRNA. *RNA*. 2002;8:1253–66.
28. Alexandrov A, Grayhack EJ, Phizicky EM. tRNA m7G methyltransferase Trm8p/Trm82p: evidence linking activity to a growth phenotype and implicating Trm82p in maintaining levels of active Trm8p. *RNA*. 2005;11:821–30.
29. Leulliot N, Chaillet M, Durand D, Ulryck N, Blondeau K, van Tilbeurgh H. Structure of the yeast tRNA m7G methylation complex. *Structure*. 2008;16:52–61.
30. Chan CT, Dyavaiah M, DeMott MS, Taghizadeh K, Dedon PC, Begley TJ. A quantitative systems approach reveals dynamic control of tRNA modifications during cellular stress. *PLoS Genet*. 2010;6:e1001247.
31. Chan CT, Pang YL, Deng W, Babu IR, Dyavaiah M, Begley TJ, et al. Reprogramming of tRNA modifications controls the oxidative stress response by codon-biased translation of proteins. *Nat Commun*. 2012;3:937.
32. Preston MA, D'Silva S, Kon Y, Phizicky EM. tRNAHis 5-methylcytidine levels increase in response to several growth arrest conditions in *Saccharomyces cerevisiae*. *RNA*. 2013;19:243–56.
33. Bartlett JM, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, et al. Mammostrat® as patients at risk of recurrence during endocrine therapy. *Breast Cancer Res*. 2010;12:R47.
34. Takeoka S, Unoki M, Onouchi Y, Doi S, Fujiwara H, Miyatake A, et al. Amino-acid substitutions in the IKAP gene product significantly increase risk for bronchial asthma in children. *J Hum Genet*. 2001;46:57–63.
35. Strug LJ, Clarke T, Chiang T, Chien M, Baskurt Z, Li W, et al. Centrotemporal sharp wave EEG trait in rolandic epilepsy maps to Elongator Protein Complex 4 (ELP4). *Eur J Hum Genet*. 2009;17:1171–81.
36. Alazami AM, Hijazi H, Al-Dosari MS, Shaheen R, Hashem A, Aldahmesh MA, et al. Mutation in ADAT3, encoding adenosine deaminase acting on transfer RNA, causes intellectual disability and strabismus. *J Med Genet*. 2013;50:425–30.
37. Gerber AP, Keller W. An adenosine deaminase that generates inosine at the wobble position of tRNAs. *Science*. 1999;286:1146–9.
38. Jackman JE, Montange RK, Malik HS, Phizicky EM. Identification of the yeast gene encoding the tRNA m1G methyltransferase responsible for modification at position 9. *RNA*. 2003;9:574–85.
39. Igoillo-Esteve M, Genin A, Lambert N, Desir J, Piron I, Abdulkarim B, et al. tRNA methyltransferase homolog gene TRMT10A mutation in young-onset diabetes and primary microcephaly in humans. *PLoS Genet*. 2013;9:e1003888.
40. Gillis D, Krishnamohan A, Yaacov B, Shaag A, Jackman JE, Elpeleg O. TRMT10A dysfunction is associated with abnormalities in glucose homeostasis, short stature and microcephaly. *J Med Genet*. 2014;51:581–6.
41. Martinez FJ, Lee JH, Lee JE, Blanco S, Nickerson E, Gabriel S, et al. Whole exome sequencing identifies a splicing mutation in NSUN2 as a cause of a Dubowitz-like syndrome. *J Med Genet*. 2012;49:380–5.
42. Blanco S, Dietmann S, Flores JV, Hussain S, Kutter C, Humphreys P, et al. Aberrant methylation of tRNAs links cellular stress to neuro-developmental disorders. *EMBO J*. 2014;33:2020–39.
43. Fahiminiya S, Almuriekh M, Nawaz Z, Staffa A, Lepage P, Ali R, et al. Whole exome sequencing unravels disease-causing genes in consanguineous families in Qatar. *Clin Genet*. 2014;86:134–41.
44. Schaffer AE, Eggers VR, Caglayan AO, Reuter MS, Scott E, Coufal NG, et al. CLP1 founder mutation links tRNA splicing and maturation to cerebellar development and neurodegeneration. *Cell*. 2014;157:651–63.
45. Alazami AM, Patel N, Shamseldin HE, Anazi S, Al-Dosari MS, Alzahrani F, et al. Accelerating novel candidate gene discovery in neurogenetic disorders via whole-exome sequencing of prescreened multiplex consanguineous families. *Cell Rep*. 2015;10:148–61.
46. Phizicky EM, Alfonso JD. Do all modifications benefit all tRNAs? *FEBS Lett*. 2010;584:265–71.
47. Okamoto M, Fujiwara M, Hori M, Okada K, Yazama F, Konishi H, et al. tRNA modifying enzymes, NSUN2 and METTL1, determine sensitivity to 5-Fluorouracil in HeLa cells. *PLoS Genet*. 2014;10:e1004639.
48. Nedialkova DD, Leidel SA. Optimization of codon translation rates via tRNA modifications maintains proteome integrity. *Cell*. 2015;161:1606–18.
49. Anderson SL, Coli R, Daly IW, Kichula EA, Rork MJ, Volpi SA, et al. Familial dysautonomia is caused by mutations of the IKAP gene. *Am J Hum Genet*. 2001;68:753–8.
50. Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, Cuajungco MP, et al. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. *Am J Hum Genet*. 2001;68:598–605.
51. Cuajungco MP, Leyne M, Mull J, Gill SP, Lu W, Zagzag D, et al. Tissue-specific reduction in splicing efficiency of IKBKAP due to the major mutation associated with familial dysautonomia. *Am J Hum Genet*. 2003;72:749–58.
52. Freude K, Hoffmann K, Jensen LR, Delatycki MB, des Portes V, Moser B, et al. Mutations in the FTSJ1 gene coding for a novel S-adenosylmethionine-

- binding protein cause nonsyndromic X-linked mental retardation. *Am J Hum Genet.* 2004;75:305–9.
53. Ramser J, Winnepenninckx B, Lenski C, Errijgers V, Platzer M, Schwartz CE, et al. A splice site mutation in the methyltransferase gene FTSJ1 in Xp11.23 is associated with non-syndromic mental retardation in a large Belgian family (MRX9). *J Med Genet.* 2004;41:679–83.
 54. Froyen G, Bauters M, Boyle J, Van Esch H, Govaerts K, van Bokhoven H, et al. Loss of SLC38A5 and FTSJ1 at Xp11.23 in three brothers with non-syndromic mental retardation due to a microdeletion in an unstable genomic region. *Hum Genet.* 2007;121:539–47.
 55. Takano K, Nakagawa E, Inoue K, Kamada F, Kure S, Goto Y. A loss-of-function mutation in the FTSJ1 gene causes nonsyndromic X-linked mental retardation in a Japanese family. *Am J Med Genet B Neuropsychiatr Genet.* 2008;147B:479–84.
 56. Zeharia A, Shaag A, Pappo O, Mager-Heckel AM, Saada A, Beinat M, et al. Acute infantile liver failure due to mutations in the TRMU gene. *Am J Hum Genet.* 2009;85:401–7.
 57. Najmabadi H, Hu H, Garshasbi M, Zemojtel T, Abedini SS, Chen W, et al. Deep sequencing reveals 50 novel genes for recessive cognitive disorders. *Nature.* 2011;478:57–63.
 58. Abbasi-Moheb L, Mertel S, Gonsior M, Nouri-Vahid L, Kahrizi K, Cirak S, et al. Mutations in NSUN2 cause autosomal-recessive intellectual disability. *Am J Hum Genet.* 2012;90:847–55.
 59. Khan MA, Rafiq MA, Noor A, Hussain S, Flores JV, Rupp V, et al. Mutation in NSUN2, which encodes an RNA methyltransferase, causes autosomal-recessive intellectual disability. *Am J Hum Genet.* 2012;90:856–63.
 60. Yarham JW, Lamichhane TN, Pyle A, Mattijssen S, Baruffini E, Bruni F, et al. Defective i6A37 modification of mitochondrial and cytosolic tRNAs results from pathogenic mutations in TRIT1 and its substrate tRNA. *PLoS Genet.* 2014;10:e1004424.
 61. Alkuraya FS. Discovery of rare homozygous mutations from studies of consanguineous pedigrees. *Curr Protoc Hum Genet.* 2012, Chapter 6: Unit 6 12.
 62. Carr IM, Flintoff KJ, Taylor GR, Markham AF, Bonthron DT. Interactive visual analysis of SNP data for rapid autozygosity mapping in consanguineous families. *Hum Mutat.* 2006;27:1041.
 63. Alkuraya FS. The application of next-generation sequencing in the autozygosity mapping of human recessive diseases. *Hum Genet.* 2013;132:1197–211.
 64. Guy MP, Podyma BM, Preston MA, Shaheen HH, Krivos KL, Limbach PA, et al. Yeast Trm7 interacts with distinct proteins for critical modifications of the tRNAPhe anticodon loop. *RNA.* 2012;18:1921–33.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

